A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma
Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 June 2025
|
| In: |
Cell reports. Medicine
Year: 2025, Jahrgang: 6, Heft: 6, Pages: 1-12 |
| ISSN: | 2666-3791 |
| DOI: | 10.1016/j.xcrm.2025.102165 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.xcrm.2025.102165 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2666379125002381 
|
| Verfasserangaben: | Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clement, Thomas R. Jeffry Evans, Heinz Läubli, Patrick Roth, Rebecca Kristeleit, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Benjamin Wunderlich, Kirk Beebe, Joel Robert Eisner, Heidi Lane, Marc Engelhardt, Thomas Kaindl, Peter Hau, Thomas Hundsberger, and Joachim Steinbach |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949549291 | ||
| 003 | DE-627 | ||
| 005 | 20260119095228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260119s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2025.102165 |2 doi | |
| 035 | |a (DE-627)1949549291 | ||
| 035 | |a (DE-599)KXP1949549291 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lopez, Juanita Suzanne |e VerfasserIn |0 (DE-588)1387112546 |0 (DE-627)1949549887 |4 aut | |
| 245 | 1 | 2 | |a A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma |c Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clement, Thomas R. Jeffry Evans, Heinz Läubli, Patrick Roth, Rebecca Kristeleit, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Benjamin Wunderlich, Kirk Beebe, Joel Robert Eisner, Heidi Lane, Marc Engelhardt, Thomas Kaindl, Peter Hau, Thomas Hundsberger, and Joachim Steinbach |
| 264 | 1 | |c 17 June 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 17. Juni 2025, Artikelversion: 17. Juni 2025 | ||
| 500 | |a Gesehen am 19.01.2026 | ||
| 520 | |a Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800). | ||
| 650 | 4 | |a astrocytoma | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a glioma | |
| 650 | 4 | |a lisavanbulin | |
| 700 | 1 | |a Haefliger, Simon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Plummer, Ruth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clement, Paul M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jeffry Evans, Thomas R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Läubli, Heinz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roth, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kristeleit, Rebecca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brazil, Lucy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tabatabai, Ghazaleh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 700 | 1 | |a Wunderlich, Benjamin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beebe, Kirk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eisner, Joel Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lane, Heidi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engelhardt, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaindl, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hau, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hundsberger, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steinbach, Joachim |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d Cambridge, MA : Cell Press, 2020 |g 6(2025), 6 vom: Juni, Artikel-ID 102165, Seite 1-12 |h Online-Ressource |w (DE-627)1696877792 |w (DE-600)3019420-9 |x 2666-3791 |7 nnas |a A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma |
| 773 | 1 | 8 | |g volume:6 |g year:2025 |g number:6 |g month:06 |g elocationid:102165 |g pages:1-12 |g extent:12 |a A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.xcrm.2025.102165 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2666379125002381 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260119 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 910000 |d 911100 |d 50000 |e 910000PW122759869 |e 911100PW122759869 |e 50000PW122759869 |k 0/910000/ |k 1/910000/911100/ |k 0/50000/ |p 11 | ||
| 999 | |a KXP-PPN1949549291 |e 4854312254 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Lopez, Juanita Suzanne","family":"Lopez","role":"aut","given":"Juanita Suzanne"},{"given":"Simon","role":"aut","display":"Haefliger, Simon","family":"Haefliger"},{"given":"Ruth","role":"aut","display":"Plummer, Ruth","family":"Plummer"},{"display":"Clement, Paul M.","family":"Clement","given":"Paul M.","role":"aut"},{"given":"Thomas R.","role":"aut","display":"Jeffry Evans, Thomas R.","family":"Jeffry Evans"},{"display":"Läubli, Heinz","family":"Läubli","role":"aut","given":"Heinz"},{"role":"aut","given":"Patrick","family":"Roth","display":"Roth, Patrick"},{"display":"Kristeleit, Rebecca","family":"Kristeleit","role":"aut","given":"Rebecca"},{"display":"Brazil, Lucy","family":"Brazil","given":"Lucy","role":"aut"},{"given":"Ghazaleh","role":"aut","display":"Tabatabai, Ghazaleh","family":"Tabatabai"},{"given":"Antje","role":"aut","family":"Wick","display":"Wick, Antje"},{"given":"Benjamin","role":"aut","family":"Wunderlich","display":"Wunderlich, Benjamin"},{"display":"Beebe, Kirk","family":"Beebe","given":"Kirk","role":"aut"},{"role":"aut","given":"Joel Robert","display":"Eisner, Joel Robert","family":"Eisner"},{"family":"Lane","display":"Lane, Heidi","given":"Heidi","role":"aut"},{"role":"aut","given":"Marc","family":"Engelhardt","display":"Engelhardt, Marc"},{"role":"aut","given":"Thomas","family":"Kaindl","display":"Kaindl, Thomas"},{"role":"aut","given":"Peter","display":"Hau, Peter","family":"Hau"},{"display":"Hundsberger, Thomas","family":"Hundsberger","role":"aut","given":"Thomas"},{"family":"Steinbach","display":"Steinbach, Joachim","role":"aut","given":"Joachim"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma","title_sort":"phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma"}],"note":["Online verfügbar: 17. Juni 2025, Artikelversion: 17. Juni 2025","Gesehen am 19.01.2026"],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"17 June 2025"}],"id":{"doi":["10.1016/j.xcrm.2025.102165"],"eki":["1949549291"]},"physDesc":[{"extent":"12 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clement, Thomas R. Jeffry Evans, Heinz Läubli, Patrick Roth, Rebecca Kristeleit, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Benjamin Wunderlich, Kirk Beebe, Joel Robert Eisner, Heidi Lane, Marc Engelhardt, Thomas Kaindl, Peter Hau, Thomas Hundsberger, and Joachim Steinbach"]},"recId":"1949549291","relHost":[{"part":{"year":"2025","pages":"1-12","text":"6(2025), 6 vom: Juni, Artikel-ID 102165, Seite 1-12","issue":"6","extent":"12","volume":"6"},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastomaCell reports. Medicine","pubHistory":["Volume 1, issue 1 (2020)-"],"origin":[{"publisherPlace":"Cambridge, MA ; Maryland Heights, MO","publisher":"Cell Press ; Elsevier","dateIssuedDisp":"[2020]-"}],"note":["Gesehen am 29. April 2020"],"title":[{"partname":"Medicine","title_sort":"Cell reports","title":"Cell reports"}],"id":{"zdb":["3019420-9"],"issn":["2666-3791"],"eki":["1696877792"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"1696877792"}]} | ||
| SRT | |a LOPEZJUANIPHASE12ADO1720 | ||